Daphne Lobeek1, Gerben M Franssen2, Michelle T Ma3, Hans-Jürgen Wester4, Clemens Decristoforo5, Wim J G Oyen2,6, Otto C Boerman2, Samantha Y A Terry3, Mark Rijpkema2. 1. Department of Radiology and Nuclear Medicine, Radboud University Medical Center Nijmegen, Nijmegen, The Netherlands daphne.lobeek@radboudumc.nl. 2. Department of Radiology and Nuclear Medicine, Radboud University Medical Center Nijmegen, Nijmegen, The Netherlands. 3. Department of Imaging Chemistry and Biology, King's College London, London, United Kingdom. 4. Pharmazeutische Radiochemie, Technische Universität München, Garching, Germany. 5. Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, Austria; and. 6. Institute of Cancer Research and Royal Marsden NHS Trust, Department of Nuclear Medicine, London, United Kingdom.
Abstract
αvβ3 integrins play an important role in angiogenesis and cell migration in cancer and are highly expressed on the activated endothelial cells of newly formed blood vessels. Here, we compare the targeting characteristics of 4 68Ga-labeled multimeric cyclic arginine-glycine-aspartate (RGD)-based tracers in an αvβ3 integrin-expressing tumor model and a tumor model in which αvβ3 integrin is expressed solely on the neovasculature. Methods: Female BALB/c nude mice were subcutaneously injected with SK-RC-52 (αvβ3 integrin-positive) or FaDu (αvβ3 integrin-negative) tumor cells. 68Ga-labeled DOTA-(RGD)2, TRAP-(RGD)3, FSC-(RGD)3, or THP-(RGD)3 was intravenously administered to the mice (0.5 nmol per mouse, 10-20 MBq), followed by small-animal PET/CT imaging and ex vivo biodistribution studies 1 h after injection. Nonspecific uptake of the tracers in both models was determined by coinjecting an excess of unlabeled DOTA-(RGD)2 (50 nmol) along with the radiolabeled tracers. Results: Imaging and biodistribution data showed specific uptake in the tumors for each tracer in both models. Tumor uptake of 68Ga-FSC-(RGD)3 was significantly higher than that of 68Ga-DOTA-(RGD)2, 68Ga-TRAP-(RGD)3, or 68Ga-THP-(RGD)3 in the SK-RC-52 model but not in the FaDu model, in which 68Ga-FSC-(RGD)3 showed significantly higher tumor uptake than 68Ga-TRAP-(RGD)3 Most importantly, differences were also observed in normal tissues and in tumor-to-blood ratios. Conclusion: All tracers showed sufficient targeting of αvβ3 integrin expression to allow for tumor detection. Although the highest tumor uptake was found for 68Ga-FSC-(RGD)3 and 68Ga-THP-(RGD)3 in the SK-RC-52 and FaDu models, respectively, selection of the optimal tracer for specific diagnostic applications also depends on tumor-to-blood ratio and uptake in normal tissues; these factors should therefore also be considered.
αvβ3 integrins play an important role in angiogenesis and cell migration in cancer and are highly expressed on the activated endothelial cells of newly formed blood vessels. Here, we compare the targeting characteristics of 4 68Ga-labeled multimeric cyclic arginine-glycine-aspartate (RGD)-based tracers in an αvβ3 integrin-expressing tumor model and a tumor model in which αvβ3 integrin is expressed solely on the neovasculature. Methods: Female BALB/c nude mice were subcutaneously injected with SK-RC-52 (αvβ3 integrin-positive) or FaDu (αvβ3 integrin-negative) tumor cells. 68Ga-labeled DOTA-(RGD)2, TRAP-(RGD)3, FSC-(RGD)3, or THP-(RGD)3 was intravenously administered to the mice (0.5 nmol per mouse, 10-20 MBq), followed by small-animal PET/CT imaging and ex vivo biodistribution studies 1 h after injection. Nonspecific uptake of the tracers in both models was determined by coinjecting an excess of unlabeled DOTA-(RGD)2 (50 nmol) along with the radiolabeled tracers. Results: Imaging and biodistribution data showed specific uptake in the tumors for each tracer in both models. Tumor uptake of 68Ga-FSC-(RGD)3 was significantly higher than that of 68Ga-DOTA-(RGD)2, 68Ga-TRAP-(RGD)3, or 68Ga-THP-(RGD)3 in the SK-RC-52 model but not in the FaDu model, in which 68Ga-FSC-(RGD)3 showed significantly higher tumor uptake than 68Ga-TRAP-(RGD)3 Most importantly, differences were also observed in normal tissues and in tumor-to-blood ratios. Conclusion: All tracers showed sufficient targeting of αvβ3 integrin expression to allow for tumor detection. Although the highest tumor uptake was found for 68Ga-FSC-(RGD)3 and 68Ga-THP-(RGD)3 in the SK-RC-52 and FaDu models, respectively, selection of the optimal tracer for specific diagnostic applications also depends on tumor-to-blood ratio and uptake in normal tissues; these factors should therefore also be considered.
Authors: Samantha Y A Terry; Keelara Abiraj; Jasper Lok; Danny Gerrits; Gerben M Franssen; Wim J G Oyen; Otto C Boerman Journal: J Nucl Med Date: 2014-10-27 Impact factor: 10.057
Authors: Ingrid Dijkgraaf; John A W Kruijtzer; Shuang Liu; Annemieke C Soede; Wim J G Oyen; Frans H M Corstens; Rob M J Liskamp; Otto C Boerman Journal: Eur J Nucl Med Mol Imaging Date: 2006-08-15 Impact factor: 9.236
Authors: Cinzia Imberti; Samantha Y A Terry; Carleen Cullinane; Fiona Clarke; Georgina H Cornish; Nisha K Ramakrishnan; Peter Roselt; Andrew P Cope; Rodney J Hicks; Philip J Blower; Michelle T Ma Journal: Bioconjug Chem Date: 2016-12-14 Impact factor: 4.774
Authors: Riikka Siitonen; Emilia Peuhu; Anu Autio; Heidi Liljenbäck; Elina Mattila; Olli Metsälä; Meeri Käkelä; Tiina Saanijoki; Ingrid Dijkgraaf; Sirpa Jalkanen; Johanna Ivaska; Anne Roivainen Journal: J Nucl Med Date: 2019-03-08 Impact factor: 10.057
Authors: Yujing Du; Zhao Chen; Xiaojiang Duan; Ping Yan; Chunli Zhang; Lei Kang; Rongfu Wang Journal: Ann Nucl Med Date: 2022-01-15 Impact factor: 2.668
Authors: Ruslan Cusnir; Andrew Cakebread; Margaret S Cooper; Jennifer D Young; Philip J Blower; Michelle T Ma Journal: RSC Adv Date: 2019-11-14 Impact factor: 4.036
Authors: Daphne Lobeek; Frédérique C M Bouwman; Erik H J G Aarntzen; Janneke D M Molkenboer-Kuenen; Uta E Flucke; Ha-Long Nguyen; Miikka Vikkula; Laurence M Boon; Willemijn Klein; Peter Laverman; Wim J G Oyen; Otto C Boerman; Samantha Y A Terry; Leo J Schultze Kool; Mark Rijpkema Journal: J Nucl Med Date: 2019-09-13 Impact factor: 10.057
Authors: Cinzia Imberti; Yu-Lin Chen; Calum A Foley; Michelle T Ma; Brett M Paterson; Yifu Wang; Jennifer D Young; Robert C Hider; Philip J Blower Journal: Dalton Trans Date: 2019-03-26 Impact factor: 4.390
Authors: D Lobeek; M Rijpkema; S Y A Terry; J D M Molkenboer-Kuenen; L Joosten; E A J van Genugten; A C H van Engen-van Grunsven; J H A M Kaanders; S A H Pegge; O C Boerman; W L J Weijs; M A W Merkx; C M L van Herpen; R P Takes; E H J G Aarntzen; W J G Oyen Journal: Eur J Nucl Med Mol Imaging Date: 2020-03-20 Impact factor: 9.236
Authors: Vanessa F Schmidt; Max Masthoff; Michael Czihal; Beatrix Cucuruz; Beate Häberle; Richard Brill; Walter A Wohlgemuth; Moritz Wildgruber Journal: Mol Cell Pediatr Date: 2021-12-07